Application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines

A functional bacterial agent, bifidobacteria technology, applied in bifidobacteria, bacteria used in food preparation, applications, etc., can solve problems such as liver function damage and edema, increased drug toxicity and side effects, and adverse reactions in the digestive tract. To achieve the effect of improving the increase of total cholesterol, strong adsorption capacity and alleviating the toxicity of PFOA

Active Publication Date: 2019-10-22
JIANGNAN UNIV
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs have a certain therapeutic effect, but as the disease worsens, the dosage increases, drug interactions, and drug side effects also increase significantly, leading to adverse reactions in the digestive tract and showing certain liver and kidney toxicity, such as Long-term use of metformin can cause discomfort in the gastrointestinal tract of some patients and may affect the absorption of vitamin B12. Rosiglitazone can cause liver damage and edema, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines
  • Application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines
  • Application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and/or medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1: Bifidobacterium adolescentis CCFM1061 has good tolerance to simulated gastrointestinal fluid

[0061] Inoculate cryopreserved Bifidobacterium adolescentis CCFM1061 in mMRS medium (MRS medium + 0.05% cysteine ​​hydrochloride), culture anaerobically at 37°C for 48 hours, and subculture in mMRS medium for 2-3 After the second time, take 1 mL of the culture solution of Bifidobacterium adolescentis CCFM1061, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (mMRS medium containing 1% pepsin, pH = 2.5), and culture it anaerobically at 37°C, respectively. Samples were taken at 0h, 0.5h, 1h, and 2h, and the mMRS agar medium was poured to culture the plate colonies, and the number of viable bacteria was determined and the survival rate was calculated.

[0062] The survival rate is the ratio of the logarithmic value of the number of viable bacteria at the time of sampling to the logarithmic value of the number of viable bacteria at the 0th hour in the cul...

Embodiment 2

[0068] Example 2: Bifidobacterium adolescentis CCFM1061 has no toxic side effects on C57BL / 6J mice

[0069] The Bifidobacterium adolescentis CCFM1061 bacteria were resuspended in 3% sucrose solution to make a concentration of 3.0×10 9 CFU / mL bacterial suspension. Eight healthy male C57BL / 6J mice with a body weight of about 16-20 g were taken. After one week of adaptation to the environment, the bacterial suspension of this concentration was administered orally once a day, observed for one week, and the death and body weight were recorded.

[0070] The results of these tests are listed in Table 3. These results indicate that feeding concentrations of 3.0×10 9 CFU / mL of Bifidobacterium adolescentis CCFM1061 had no significant effect on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0071] Table 3 Changes in body weight and death of mice

[0072]

[0073] Note: -: no death of mice

Embodiment 3

[0074] Embodiment 3: Bifidobacterium adolescentis CCFM1061 can reduce (fasting) blood sugar level in type 2 diabetic mice

[0075] Take 40 healthy male C57BL / 6J mice weighing 16-20g, adapt to the environment for 1 week, and divide them into 5 groups randomly: blank control group (NC), model control group (M), rosiglitazone control group (RH) , Bifidobacterium adolescentis CCFM1061 intervention group (CCFM1061), Bifidobacterium adolescentis BA1 control group (BA1) each group contained 8 mice, and the dose of intragastric bacterial suspension was 3.0×10 9 CFU / mL, resuspended in 3% sucrose solution. The grouping and treatment methods of experimental animals are shown in Table 4:

[0076] Table 4 Grouping of experimental animals

[0077]

[0078]

[0079] Week 2-7: The mice in the normal group were fed with normal feed, and the rest of the mice were fed with high-fat feed.

[0080] On the 1st day of the 11th week, all mice were fasted for 12 hours, the normal group was in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and / or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

Description

technical field [0001] The invention belongs to the technical field, and specifically relates to the application of Bifidobacterium adolescentis CCFM1061 in the preparation of functional bacterial agents, food and / or medicine. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is fatty degeneration caused by excessive accumulation of fat in liver cells. It is a symptom of liver metabolic disorders. Without intervention, it can gradually evolve into non-alcoholic fat Hepatitis (NASH) further deteriorates into liver fibrosis, liver cirrhosis, and liver cancer with extremely high mortality rates. In recent years, with the improvement of living standards, more and more high-fat and high-energy diets are put on the table, but people's exercise has not increased accordingly, which makes metabolic syndrome represented by non-alcoholic fatty liver disease The incidence of symptoms is increasing year by year. Due to its imperfect pathological mechanism, there a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/745A61P3/10A23L33/135
CPCA61K35/745A61P3/10A23L33/135A23V2002/00A23V2200/328A23V2200/32A23V2200/30A23V2400/513
Inventor 陈卫王刚司倩赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap